CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 5, 2017--
AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey,
president and chief executive officer, will be presenting at the
following investor conferences:
The 19th Annual Rodman & Renshaw Global Investment
Conference on Tuesday, September 12, 2017 at 9:35 a.m. Eastern Time.
The conference is being held at the Lotte New York Palace Hotel.
The Cantor Fitzgerald 2017 Global Healthcare Conference on Wednesday,
September 27, 2017 at 4:00 p.m. Eastern Time. The conference is being
held at the InterContinental New York Barclay Hotel.
A live webcast of the presentations can be accessed by visiting the
investors section of the Company’s website at www.aveooncology.com.
A replay of the webcast will be archived for 30 days following the
AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to
advancing a broad portfolio of targeted therapeutics for oncology and
other areas of unmet medical need. The Company is focused on seeking to
develop and commercialize its lead candidate tivozanib, a potent,
selective, long half-life inhibitor of vascular endothelial growth
factor 1, 2 and 3 receptors, in North America as a treatment for renal
cell carcinoma and other cancers. AVEO is leveraging multiple
partnerships aimed at developing and commercializing tivozanib in
oncology indications outside of North America, and at progressing its
pipeline of novel therapeutic candidates in cancer and cachexia (wasting
syndrome). Tivozanib (FOTIVDA®) is approved by the European
Commission for the treatment of adult patients with advanced renal cell
carcinoma (RCC) in the European Union plus Norway and Iceland. For more
information, please visit the company’s website at www.aveooncology.com.
AVEO Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO that
involve substantial risks and uncertainties. All statements, other than
statements of historical fact, contained in this press release are
forward-looking statements. Actual results or events could differ
materially due to a number of important factors, including risks
discussed in the section titled “Risk Factors” in AVEO’s most recent
Annual Report on Form 10-K, its quarterly reports on Form 10-Q and its
other filings with the SEC. The forward-looking statements in this press
release represent AVEO’s views as of the date of this press release.
AVEO anticipates that subsequent events and developments may cause its
views to change. While AVEO may elect to update these forward-looking
statements at some point in the future, it specifically disclaims any
obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing AVEO’s views as of any date
other than the date of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170905005163/en/
Source: AVEO Oncology
David Pitts, (212) 600-1902